The FDA approved and granted emergency use authorization (EUA) to update the mRNA COVID-19 vaccines for 2024-2025, which include a monovalent component that corresponds to the omicron variant KP.2 strain of SARS-CoV-2.
The mRNA COVID-19 vaccines by Moderna and Pfizer-BioNTech have updated the formula to more closely target circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death, the FDA said in a